Acrivon Therapeutics Inc Sustainability Reports
A clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 platform to match drugs with patients whose tumors are predicted to be sensitive to the treatment.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
1 reports from 2023 to 2023
Company Profile
A clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 platform to match drugs with patients whose tumors are predicted to be sensitive to the treatment.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
